Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment ...Middle East

– Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 – – Phase 3 SENTRY Results Selected for Late-Breaking Oral Presentation at ASCO on June 2 – – Total Revenue was $35.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $29....

Hence then, the article about karyopharm reports first quarter 2026 financial results and completion of phase 3 endometrial cancer trial enrollment was published today ( Thursday 14/05/2026 - 02:32 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment )

Also on site :

• Twins To Recall Zebby Matthews
• Nepal in a bind as US-China drone war reaches Everest
• Polestar CEO tells CNBC ‘pump anxiety’ has made EVs ‘all about money’